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Abstract
The use of biomarkers in medicine lies in their ability to detect disease and support diagnostic and
therapeutic decisions. New research and novel understanding of the molecular basis of the disease
reveals an abundance of exciting new biomarkers who present a promise for use in the everyday
clinical practice. The past fifteen years have seen the emergence of numerous clinical applications
of several new molecules as biologic markers in the research field relevant to acute respiratory
distress syndrome (translational research). The scope of this review is to summarize the current
state of knowledge about serum biomarkers in acute lung injury and acute respiratory distress
syndrome and their potential value as prognostic tools and present some of the future perspectives
and challenges.
Introduction
The use of biomarkers in medicine lies in their ability to
detect disease and support diagnostic and therapeutic
decisions. New research and novel understanding of the
molecular basis of the disease reveals an abundance of
exciting new biomarkers who present a promise for use in
the everyday clinical practice.
The initial evaluation of a serum biomarker concerns its
expression in patients with the disease and in normal
individuals in order to define sensitivity and specificity.
The sensitivity of a test is defined as the proportion of
patients with disease having a positive test whereas the
specificity is the proportion of patients without the dis-
ease who have a negative or normal test. Consequently the
serum level of an ideal marker should: 1) increase patho-
logically in the presence of the disease (high sensitivity),
2) not increase in the absence of the disease (high specif-
icity), 3) relate to the disease burden and extent, 4) change
in accordance with the clinical evolution, reflecting the
current status of disease, or better 5) anticipate clinical
changes, i.e. indicating the presence of relapse before it
becomes obvious at a clinical level and finally 6) possess
constant serum levels (no major fluctuation) [1].
Additionally, a clinically suitable biomarker should fulfil
the following requirements [2]:
1. add independent information about the risk or
prognosis
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2. account for a large proportion of the risk associated
with a given disease or condition
3. be reproducible (as determined by the low coefficient
of variation)
4. be sensitive, specific and should present with a high
predictive value
5. be of easy and cheap determination
Very few markers present a threshold at which the risk
suddenly rises. The interplay between sensitivity and spe-
cificity and the nature of the disease under prediction
assigns suitable cut-off points. Sensitivity and specificity
calculated at various cut-off points give rise to a receiver-
operating-characteristic (ROC) curve [2]. A clinically use-
ful biomarker will be one with the largest area under the
ROC curve. A number of novel blood biomarkers of lung
disease including cytokines, enzymes, adhesion mole-
cules, collagen relevant products and products of type II
epithelial cells, have been studied for their clinical
applicability.
The scope of this review is based on the fact that although
there are numerous published papers investigating the
utility of biomarkers in the clinical research field the
number of review articles summarizing the current state of
knowledge about the clinical applications of these mole-
cules as diagnostic and prognostic tools in the research
field relevant to acute respiratory distress syndrome
(ARDS) and acute lung injury (ALI) still remains inade-
quately small.
Serum biomarkers in Acute Respiratory 
Distress syndrome
ARDS is a clinical and pathophysiologic entity character-
ized by severe acute injury, directly or indirectly via the
blood, to the endothelial and epithelial surfaces of the
lung leading to respiratory failure. The main characteris-
tics of the syndrome are diffuse inflammation and
increased microvascular permeability that cause diffused
interstitial and alveolar oedema and persistent refractory
hypoxemia [3]. Although a variety of insults may lead to
ARDS, a common pathway may probably result in the
lung damage [4,5]. A complex series of inflammatory
events have been recognized during the development of
ARDS but the exact sequence of the events remains elu-
sive. Immunological studies investigating bronchoalveo-
lar lavage fluid (BALF) have shed further light into the
pathogenetic mechanisms of ARDS [6] and formed the
basis of concepts of its immunopathogenesis. A large vari-
ety of inflammatory mediators (Table 1) have been found
to be elevated in the early phase of ARDS, including lung-
specific proteins, endotoxin binding proteins, tumor
necrosis-alpha (TNFa), interleukins – (ILs) – 1, 2, 6, 8, 15,
chemokines, ferritin, markers of endothelium activation
(adhesive molecules and von-Willebrand factor antigen-
VWF) as well as markers of neutrophil activation such as
matrix metalloproteinases (MMPs) and their inhibitors
and leukotrienes [5-7]. The majority of these molecules
have features to recommend them as biologic markers in
ARDS. Biomarkers have attracted a lot of attention in both
ALI and ARDS since they can shed further light into the
pathogenesis and pathophysiology of lung injury. Addi-
tionally, from a practical point of view, a clinical useful
biomarker for ARDS must add information regarding the
development of syndrome in at-risk patients that is not
apparent from routine examination and investigation.
The latter, could help the intensivist to monitor the dis-
ease and evaluate or modulate treatments before they
have failed. Driven by this perspective idea, many studies
have estimated their usefulness as early predictors of
ARDS and accurate markers of lung injury before clinical
changes can be detected.
Table 1: List of studied serum biomarkers in ARDS
Lung epithelium-
specific proteins
Surfactant-associated proteins
• SP-A
• SP-B
• SP-D
Mucin-associated antigens
• KL-6/MUC1
Cytokines • IL-1
• IL-2
• IL-6
• IL-8
• IL-10
• IL-15
• TNFa
Other serological 
parameters
Markers of endothelium activation
• Adhesion molecules 
(E, L-selectin, I-CAM-1, V-CAM-1)
• VWF
Markers of neutrophil activation
• MMP-9
• LTB4
Ferritin
Abbreviations: ARDS: Acute Respiratory Distress Syndrome, CC16: 
Clara-cell protein 16, IL: Interleukin, KL-6: Krebs von den Lungen-6, 
LTB4: Leukotriene B4 MMP-9: Metalloproteinase-9 MUC: Mucin, I-
CAM-1: Intercellular Adhesion Molecule-1, sIL-2R: soluble interleukin-
2 receptor, V-CAM-1: Vascular Adhesion Molecule-1, VWF: von 
Willebrand factor antigenRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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Cytokines (Tables 2 and 3)
Cytokines are widely recognized as mediators of an
inflammatory response. Their discovery has stimulated
multidisciplinary investigation to elucidate the role of
these mediators in the injury and repair processes of
human disease. In the lung, they are produced either by
local resident cells such as alveolar macrophages, pneu-
mocytes, endothelial cells and fibroblasts or by cells such
as neutrophils, lymphocytes and platelets arriving to the
lung in response to local or systemic injury [8,9].
Cytokines are involved both in the early (TNFa, IL-1, 2, 6,
8, 15) and late phase (IL-4) of inflammation and have
been shown unequivocally to be of crucial importance in
the pathophysiology of septic shock, a condition fre-
quently culminating to ARDS [10,11].
Studies have demonstrated that in ARDS patients detecta-
ble cytokine serum levels are closely related to the disease
severity and mortality [11,12], suggesting a potential role
in reflecting the severity of the lung injury. Moreover,
humoral (IL-6, IL-8) and cellular markers (CD 11b) of sys-
temic inflammation have been delineated to identify
patients with septic shock at risk for organ failure, culmi-
nating to a fatal outcome [13,14]. However, their moni-
toring and prognostic value in septic-shock patients still
remains controversial. Calandra et al. [15] stated that
serum cytokines could not be used as a routine laboratory
test to predict the outcome in septic-shock patients. In
addition, Kiehl et al. [16] failed to prove usefulness of
plasma cytokines measurement for the evaluation of
severity and course of ARDS in a small cohort of leukocy-
topenic septic-shock patients. In the same study, estima-
tion of BALF levels appeared to differentiate between
responders and non-responders to treatment before clini-
cal differences become apparent. Nonetheless, it should
be noted that the small sample size, the contradictive
results, the lack of standardization techniques and uni-
form definitions for ARDS and at risk patients, together
with the heterogeneity of the syndrome and the patients
studied generate major concerns regarding the reproduci-
bility and the reliability of the data presented. Conse-
Table 2: Studies measuring cytokines in patients with or at risk for ARDS
Investigator Patients 
Controls
Biomarker / Summary ROC curve analysis 
Cut-off values
Specificity – 
Sensitivity PPV – 
NPV
Limitations
Pinsky et al. 13 52 at risk Relation of IL-6 and TNF 
plasma levels to multiple-
system organ failure and 
mortality
No Not estimated Small number of patients
No ROC curve analysis / 
cut-off levels
No serial measurement
Takala et al. 14 20 at risk
56 controls
IL-6 and IL-8 plasma levels 
predict organ failure in 
community-acquired septic 
shock
No Not estimated Small number of patients
No ROC curve analysis / 
cut-off levels
Poor discriminative value of 
serum biomarkers per se
Calandra et al. 15 70 at risk IL-6 plasma levels do not 
predict the outcome in at risk 
patients for ARDS
No Not reported Small number of patients
No ROC curve analysis
Kiehl et al. 16 19 at risk TNFa, IL-6, IL-8 plasma levels 
fail to associate with severity 
and course of ARDS in 
leukocytopenic patients
No Not estimated Small number of patients
No ROC curve analysis / 
cut-off levels
Leukocytopenic patients
Meduri et al. 18 27 ARDS TNFa, IL-1β , IL-2, IL-4, IL-6, 
IL-8
Superiority of IL-1β  and IL-6 
plasma levels in monitoring 
disease activity over 
commonly applied 
clinicophysiologic 
parameters.
Yes
TNFa: 400 pg/ml
IL-1β : 400 pg/ml
IL-2: 200 pg/ml
IL-4: 200 pg/ml
IL-6: 400 pg/ml
IL-8: 400 pg/ml
TNFa: 89-50-85-57%
IL-1β : 78-83-83-78%
IL-2: 89-83-90-80%
IL-4: 89-50-85-57%
IL-6: 77-75-81-70%
IL-8: 66-50-66-50%
Small number of patients
Perspective study
Overlap of cytokine levels 
between survivors and non-
survivors
Heterogeneity of studied 
population
Definition criteria of ARDS
Agouridakis et al. 19 8 ARDSa
26 at risk
Association between 
increased levels of IL-2 and 
IL-15 and outcome in patients 
with early ARDS
Yes
IL-2: 173 pg/ml
IL-15: 250 pg/ml
IL-2: 100-100-100-
100% IL-15: 100-100-
100-100%
Small number of patients
Limited number of studied 
molecules
Abbreviations: ARDS: Acute Respiratory Distress Syndrome, BALF: Bronchoalveolar lavage Fluid, IL: Interleukin, NPV: Negative Predictive Value, 
PPV: Positive Predictive Value, ROC: Receiver Operating Characteristic, sIL-2R: soluble interleukin-2 receptor, TNFa: Tumor Necrosis Factor-
alpha
a: Use the American European Consensus Conference definitionsRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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quently, there is a need for further large scale
investigations in the context of appropriate clinical trials
for any meaningful conclusions to be reached.
Evidence from preceding studies [11-13,16] give credence
to the view that the inability of the lung to repair after ALI
is the result of a persistent inflammatory stimulus that
ultimately leads to an unfavorable outcome [17]. Fueled
by this prospect, Meduri and coworkers [18] indicated a
consistent, efficient and independent predictive value for
IL-1β  and IL-6 serological concentrations over time in a
small cohort of patients with severe ARDS. They generated
ROC curve analysis and demonstrated a clear superiority
of inflammatory cytokines in monitoring disease activity
over commonly applied clinicophysiologic parameters.
However, this study exhibited substantial weaknesses
including the retrospective analysis, the small sample size
and the overlapping results between survivors and non-
survivors. These observations coupled with the heteroge-
neity of the disease and the evidence that elevated serum
Table 3: Studies measuring cytokines in patients with or at risk for ARDS
Investigator Patients 
Controls
Biomarker / Summary ROC curve analysis 
Cut-off values
Specificity – 
Sensitivity PPV – 
NPV
Limitations
Lesur et al. 20 19 ARDSa
14 at risk
20 controls
Association of early low serum
IL-2 levels with the patients' 
survival
No Not estimated Small number of patients
No ROC curve analysis / cut-
off levels
No serial measurement
Discrepancies in serum and 
BALF IL-2 levels
Limited number of studied 
molecules
Parsons et al. 23 77 at risk Association of serum IL-1ra, 
IL-10 levels with the disease 
outcome
No Not estimated No ROC curve analysis / cut-
off levels
Poor predictive value for 
ARDS development
Limited number of studied 
molecules
Takala et al. 24 52 at risk
9 ARDSa
45 controls
IL-8, IL-6, sIL-2R, E-selectin, 
procalcitonin
Persistent elevation of 
inflammatory markers in 
patients with ALI precedes its 
clinical diagnosis
No Not estimated Small number of non-
survivors
No ROC curve analysis / cut-
off levels
Poor predictive value for 
ARDS development
Bouros et al. 25 32 ARDSa
27 at risk
IL-4, IL-6, IL-6r, IL-8, IL-10
High prognostic value of all the 
inflammatory markers in 
assessing the outcome in 
patients with or at risk for 
ARDS
Yes
IL-4: 84 pg/ml
IL-6: 160 pg/ml
IL-6r: 18 pg/ml
IL-8: 2340 pg/ml
IL-10: 98 pg/ml
IL-4: 78-100-81-100%
IL-6: 59-96-69-94%
IL-6r: 78-76-76-78%
IL-8: 93-96-92-96%
IL-10: 96-92-96-93%
Small sample size
No serial measurement
Grouping and definition 
criteria
Schutte et al. 26 30 ARDSa
44 at risk
17 controls
IL-6, IL-8, TNFa
Serum levels of IL-6 and IL-8 in
ARDS and/or severe 
pneumonia, differentiate these 
entities from cardiogenic 
pulmonary oedema
No Not estimated Small number of patients
Weak correlations with 
clinical variables
No definitive predictive value 
for outcome
Overlap of cytokine levels 
between survivors and non-
survivors
No ROC curve analysis / cut-
off levels
Bauer et al. 27 46 ARDSa
20 at risk
10 controls
IL-6, IL-1b, TNFa serum levels 
associate better with the 
degree of lung injury rather 
than clarify its specific aetiology
No Not estimated Corticosteroid treatment
Inconclusive prognostic value
No serial measurement
Limited number of studied 
molecules
Abbreviations: ARDS: Acute Respiratory Distress Syndrome, BALF: Bronchoalveolar lavage Fluid, IL-1ra: Interleukin-receptor antagonist, NPV: 
Negative Predictive Value, PPV: Positive Predictive Value, ROC: Receiver Operating Characteristic, sIL-2R: soluble interleukin-2 receptor, TNFa: 
Tumor Necrosis Factor-alpha
a: Use the American European Consensus Conference definitionsRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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cytokines may reflect the increased production or
decreased clearance and not the disease activity pose
major limitations to the aforementioned findings.
In another study, Agouridakis et al. [19] evaluated both
the prognostic and predictive significance of IL-2 and IL-
15 for the development and outcome of patients at risk
who developed ARDS or patients at risk who never devel-
oped ARDS, respectively. They applied ROC curve analysis
and showed an excellent predictive value of cytokine
plasma levels in terms of specificity and sensitivity com-
pared to those observed in BALF. The most remarkable
ascertainment of this study was the emergence of the dis-
criminative usefulness of elevated IL-2 and IL-15 serolog-
ical concentrations in patients with ARDS or at risk for
ARDS. Nevertheless, the small number of patients
enrolled combined with the lack of serial measurements
throughout the clinical course of the disease and the
causal diversity of the syndrome render major uncertainty
to these findings.
On the contrary with other analyses [16,18], Lesur et al
[20] found lower blood IL-2 levels in patients with ARDS
compared to those that never developed the syndrome. In
addition, evidence of this study regarding the strong asso-
ciation of early low serum IL-2 levels with the patients'
survival corroborated earlier findings [16]. Potential criti-
cism of this study include the small number of patients
recruited, the absence of multiple time-point evaluation
of the cytokine plasma concentrations and more impor-
tantly opposite and disproportional fluctuations of IL-2
content in serum and BALF in patients with or without
ARDS.
The role of several inflammatory cytokines in monitoring
the disease activity and predicting the survival in patients
with ARDS has aroused increasing attention the past dec-
ade. One of the most intriguing aspects of the application
of these biomarkers in the daily clinical practice is the
early detection of patients admitted to the intensive care
unit (ICU) that will develop ARDS. This approach will
allow anti-inflammatory and other supportive treatments
to be evaluated or eventually modified before they have
failed. Predictive levels of inflammatory cytokines (IL-1,
IL-2, IL-6, IL-8) for ARDS development in at risk patients
have been extensively reported with controversial results
[16,17,21,22]. The importance of considering inflamma-
tory constituents of serum in patients at risk for ARDS was
initially raised by Parsons et al [23]. Authors conducted a
large prospective analysis and demonstrated that
although immunological parameters (IL-1ra and IL-10)
were elevated in patients at risk for ARDS and exhibited a
remarkable association with the disease outcome, none of
these could predict the development of the syndrome.
These observations were extended by the results of Takala
et al. [24] who showed that serum levels of inflammatory
mediators albeit their persistent elevation in patients with
unresolving ALI, preceding its clinical diagnosis, were of
poor discriminative value in patients with ALI that did or
did not develop ARDS. Nevertheless, these findings pro-
vided us with useful knowledge about the inflammation
marker profile on the days preceding diagnosis of ARDS,
indicating a potential relation of sustained inflammatory
response with a poor outcome.
With this aim in mind, Bouros et al. [25] measured pro-
spectively a slew of cytokines in the serum and BALF in
ICU patients to identify predictive factors for the course
and outcome of ARDS. The most remarkable result of this
analysis was that almost all serum molecules studied
showed a high prognostic value in assessing the outcome
in patients with or at risk for ARDS. However, laboratory
parameters failed to prove a positive correlation with the
prediction of ARDS development evidence consistent
with earlier studies [23,24]. Moreover, major caveats that
should be taken under consideration include the limited
number of patients, the lack of sufficient follow-up serum
data and the marked causal heterogeneity of the syn-
drome that could be a reason for the contradictive results
reported in previous studies [20,23-25]. Further prospec-
tive studies with sufficient statistical power are required to
validate these results and ameliorate the predictive role of
circulating inflammatory mediators in patients at risk for
ARDS.
Although the role of cytokines in the pathogenesis of
ARDS has been extensively investigated, their importance
in the differential diagnosis has not been clearly defined.
It is widely accepted that numerous insults may lead to
ARDS following a common pathway. Furthermore, a vari-
ety of conditions including severe pneumonia imitate
clinical and radiological manifestations of ARDS and
thereby it is often difficult to differentiate them. However,
this would be a fruitful application because the treatment
of these conditions differs considerably. Many groups of
investigators have attempted to produce a discriminative
systematic inflammatory profile and although much good
work has been done towards this direction, the results still
remain controversial.
Schutte and co-workers [26] provided us with a really well
done and heavily informative paper concerning the sys-
temic cytokine profile in patients with ARDS, severe pneu-
monia and cardiogenic pulmonary oedema. Authors
found remarkably and consistently elevated serum levels
of IL-6 and IL-8 in ARDS and/or severe pneumonia, differ-
entiating these entities from cardiogenic pulmonary
oedema. Nevertheless, they were unable to separate the
various entities of ARDS and states of severe pneumoniaRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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based solely on alterations in the immunomodulatory
pattern.
To streamline these observations, Bauer et al. [27] tested
the potential of inflammatory markers (TNFa, IL-1β , IL-6)
to differentiate between these two diseases. Results in har-
mony with the previous study [26] demonstrated higher
TNFa serological concentrations in patients with ARDS
from the remaining populations. However, they revealed
the ability of immunological parameters to associate bet-
ter with the degree of lung injury rather than clarify its spe-
cific aetiology. No clear relationship between serological
data and patients' survival was observed. In addition, this
data exhibits major limitations, including the absence of
uniform methodology (use of corticosteroid treatment in
some of the patients), serial measurements and the lack of
knowledge regarding serum alterations in other compo-
nents of the inflammatory network (Tables 2 and 3).
Other serological parameters
Markers of endothelium activation (Tables 4 and 5)
The pathophysiologic sequence characterizing ALI
involves apart from cytokine, free radical, proteases and
aracidonic acid metabolites release, the endothelial and
neutrophil activation which initiate a cascade of leuko-
cyte-endothelium interactions and adhesions. This is fol-
Table 4: Studies measuring markers of endothelium activation in patients with or at risk for ARDS
Investigator Patients 
Controls
Biomarker / Summary ROC curve analysis 
Cut-off values
Specificity – 
Sensitivity PPV-NPV
Limitations
Donnelly et al. 39 82 at risk
14 ARDSa
62 controls
E-selectin levels were not 
correlated with ARDS 
development and patients' 
mortality. L-selectin levels 
exhibited a significant 
prognostic value
No Not estimated Heterogeneity of studied 
population (trauma-
sepsis)
No ROC curve analysis / 
cut-off levels No serial 
measurement
Boldt et al. 40 50 at risk Constantly lower E-selectin, 
ICAM-1 and VCAM-1 levels 
in survivors experiencing 
polytrauma than in 
nonsurvivors
No Not estimated Small sample size
Causal diversity of patient 
group
No definitive association 
with patients' mortality
No ROC curve analysis / 
cut-off levels
Cowley et al. 41 40 SIRS
85 controls
Superiority of E-selectin 
plasma levels in predicting 
organ dysfunction and death 
patients with SIRS 
comparing to ICAM-1
No Not estimated Small number of patients
Causal diversity of 
patients studied
No ROC curve analysis / 
cut-off levels
Sessler et al. 43 25 at risk
12 controls
Association of elevated 
ICAM-1
Sequential plasma levels 
with the severity of shock
Yes
ICAM-1: 715 ng/ml 
(predicting survival)
Not reported Small sample size
Heterogeneity of studied 
population
Inconclusive association 
with disease Severity
Kayal et al. 44 32 at risk
9 controls
Cut off values of E-selectin, 
ICAM-1 and VWF serum 
levels predicted survival 
outcome
Yes
E-selectin: 128 ng/ml
ICAM-1: 715 ng/ml
VWF: 717%
E-selectin: 73-80-67-85%
ICAM-1: 80-90-75-92%
VWF: 87-8080-87%
Small number of patients
Most of the patients 
developed secondary ALI
Agouridakis et al. 45 23 ARDSa
42 at risk
TNFa, IL-1, ICAM-1, 
VCAM-1
ICAM-1 and VCAM-1 
showed a high NPV for 
ARDS development
Correlation with the 
disease outcome
None of the studied 
markers was an 
independent factor for 
ARDS development
Yes
TNFa: 325 pg/ml
IL-1: 225 pg/ml
ICAM-1: 300 pg/ml
VCAM-1: 260 pg/ml
For ARDS development
TNFa: 62-75-38-89%
IL-1: 58-88-39-94%
ICAM-1: 69-75-42-90%
VCAM-1: 73-88-50-95%
Small sample size
No serial measurement
None of the studied 
markers was an 
independent factor for 
ARDS development
Abbreviations: ALI: Acute Lung Injury, ARDS: Acute Respiratory Distress Syndrome, ICAM-1: Intercellular Cell Adhesion Molecule-1, IL: 
Interleukin, ROC: Receiver Operating Characteristic, SIRS: Systematic Inflammatory Response Syndrome, TNFa: Tumor Necrosis Factor-alpha, 
VCAM-1: Vascular Cell Adhesion Molecule-1, VWF: von Willebrand factor antigen, a: Use the American European Consensus Conference 
definitionsRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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lowed by transendothelial migration of neutrophils and
release of their cytotoxic products, ultimately resulting to
microvascular and tissue injury [28].
Adhesion of neutrophils to the endothelium is regulated
by at least three adhesion molecule families including
selectins (E, L and P), integrins and the immunoglobulin
superfamily (intercellular adhesion molecule- ICAM-1
and vascular cell adhesion molecule-VCAM-1) and by
chemotactic signals [29,30]. Initial interactions of leuko-
cytes and the endothelium are mediated by members of
the selectin family inducing (loose) contact with the
Table 5: Studies measuring markers of endothelium activation in patients with or at risk for ARDS
Investigator Patients 
Controls
Biomarker / Summary ROC curve analysis 
Cut-off values
Specificity – 
Sensitivity PPV-
NPV
Limitations
Rubin et al. 47 45 at risk Elevated plasma VWF is an 
early predictor of ALI in 
nonpulmonary sepsis 
syndrome
Yes
VWF: 450%
77-87-80% Small sample size 25% of 
patients had already lung 
injury at the time sepsis was 
diagnosed
Exclusion of patients who 
developed
ALI from a primary 
pulmonary source VWF 
levels measured by an old 
assay
Ware et al. 48 51 ALI/ ARDSa
4 controls
VWF is an independent 
predictor of hospital mortality 
in patients with ALI
No
VWF:450%
91-44-83-62% Inadequate sample volume
Heterogeneity of studied 
population
No ROC curve analysis
Ware et al. 49 559
ALI/ ARDSa
Significant correlation of 
elevated VWF plasma levels 
with mortality, duration of 
unassisted ventilation and 
organ failures. No differences 
of VWF levels between septic 
and non septic patients
No Not estimated Not definitive association 
with patients' mortality
Lack of knowledge regarding 
the cellular source and the 
mechanisms of elevated 
VWF serum levels
No ROC curve analysis / 
cut-off values
Moalli et al. 50 35 at risk
10 ARDS
9 controls
VWF levels were higher in 
ARDS compared with at risk
VWF levels are not helpful in 
predicting ARDS development
No Not reported Limited number of patients
No ROC curve analysis / 
cut-off values
Moss et al. 51 96 at risk VWF is not predictive of 
development of ARDS
Yes
VWF:273%
VWF:399%
47-70%
52-64%
Causal diversity of patients 
studied
No definitive relation with 
disease severity
Sabharwal et al. 52 22 ARDS
21 at risk
No significant association of 
VWF blood levels with 
patients' mortality
No Not estimated Small sample size
Retrospective study
No ROC curve analysis / 
cut-off values
Bajaj et al. 53 18 ARDS
15 at risk
27 controls
Serum VWF levels were non-
useful markers for predicting 
ARDS in at risk patients
Yes
VWF: 300%
71-62-34% Limited number of patients
No serial measurement
Coexisting multisystem 
organ failure
Heterogeneity of studied 
population
Moss et al. 54 55 at risk
14 ARDS
11 controls
ICAM-1, E-selectin, VWF
Degree of endothelial 
activation varied in patients at 
risk for ARDS from different 
etiologic factors
No Not estimated Small sample size
Heterogeneity of studied 
population
Abbreviations: ALI: Acute Lung Injury, ARDS: Acute Respiratory Distress Syndrome, ICAM-1: Intercellular Cell Adhesion Molecule-1, NPV: 
Negative Predictive Value, PPV: Positive Predictive Value, ROC: Receiver Operating Characteristic, VCAM-1: Vascular Cell Adhesion Molecule-1, 
VWF: von Willebrand factor antigen
a: Use the American European Consensus Conference definitionsRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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endothelium also known as rolling, followed by firm
adhesion requiring members of the integrin (β 2) and
immunoglobulin family (ICAM-1) [31,32].
In recent years, soluble isoforms of some of these mole-
cules {soluble-(s)-E-selectin, sICAM-1, sVCAM-1} have
been detected in the circulating blood under various
inflammatory conditions [33-35]. Mechanisms that could
potentially explain an increase in circulating adhesion
molecules include cytokine-induced (IL-1, TNFa) overex-
pression by the endothelial cells, increased proteolytic
cleavage of endothelial-bound adhesion molecules
secondary to endothelial damage or both [33,35]. One
attractive feature of these molecules and mostly E-selectin
is that since their expression is almost restricted to stimu-
lated endothelial cells [32] their presence in serum should
potentially reflect the state of endothelium in disease and
subsequently the disease severity in ALI.
Other potential markers of endothelial cell injury that
were delineated to shed further light into the pathophysi-
ologic process of ALI include von-Willebrand factor anti-
gen (VWF), a macromolecular antigen that is produced
predominantly by endothelial cells and to a lesser extent
by platelets and megakaryocytes [36]. Endothelial
perturbation (as in at risk state) or injury (as in ARDS)
results to the release of VWF from preformed stores into
the circulation [37,38]. Therefore, it appears that circulat-
ing VWF concentrations may serve as a suitable predictive
marker for development of ARDS in patients at risk.
So far, the potential usefulness of adhesion molecules and
other markers of endothelial cell damage in reflecting the
severity of endothelial damage and predicting the devel-
opment or the final outcome of the disease is a subject of
ongoing controversy. One of the first and most informa-
tive studies addressing this important issue was conducted
by Donnelly et al [39]. Authors demonstrated in a large
cohort of patients at risk for ARDS, that mean circulating
levels of sE-selectin were not correlated with subsequent
ARDS development and patients' mortality. However, low
values of sL-selectin exhibited a significant prognostic
value. In contrast, Boldt et al. [40] studying the behaviour
over 5 d of adhesion molecules (sE-selectin, sICAM-1 and
sVCAM-1) in subjects experiencing polytrauma found
constantly higher levels in nonsurvivors. In accordance to
these findings, Cowley and colleagues [41] showed a
superiority of sE-selectin plasma levels in predicting organ
dysfunction and death in a group of patients with sys-
temic inflammatory response (SIRS) comparing to
sICAM-1 peripheral concentrations. This indicated that
measurement of adhesion molecules could serve to
advantage in the management of patients with sepsis.
Nonetheless, the heterogeneity of patients studied (septic
shock and polytraumatic) may justify these controversial
results, since E-selectin expression has been found much
greater in septic than in traumatic shock in experimental
models [42].
Moreover, the relationship between the consequences of
sepsis (organ failure, mortality) and blood levels of poten-
tial markers of endothelial-cell activation was strength-
ened by Sessler and co-workers [43]. Results from this
study focusing on sICAM-1 sequential plasma levels, were
suggestive of a strong association between the severity of
shock (as determined by the presence of hypotension and
the requirement of vasoactive drugs) and the circulating
concentrations of the marker. The aforementioned obser-
vations were further confirmed by the study of Kayal et al
[44]. Cut off values for three markers of endothelial acti-
vation were determined prospectively by ROC curve anal-
ysis and clearly predicted survival outcome with high
sensitivity and specificity in a limited number of at-risk
patients with secondary ALI.
Despite that the role of soluble adhesion molecules in
other inflammatory conditions strongly associated with
ARDS [40-44] is well known, their value as markers of the
disease progression and mortality has not been exten-
sively studied in ARDS patients. To streamline these
observations, Agouridakis et al. [45] scrutinized the role
of two adhesion molecules (ICAM-1, VCAM-1) in parallel
with proinflammatory cytokines in predicting the ARDS
development and relating to the disease outcome. None
of the studied mediators was found to be an independent
factor for ARDS development, whereas both groups of
molecules exhibited a considerable negative predictive
value for ARDS development both in serum and BALF.
Additionally, ROC curve analysis showed a clear superior-
ity of plasma parameters in correlating with the disease
outcome compared with BALF molecules. Further studies
with serial BALF and serum measurements should be
designed to elucidate the exact role of these markers over
time in reflecting the disease behaviour and predicting the
likelihood of progression.
Elevated circulating concentrations of VWF in patients
with ALI/ARDS were first reported in 1982 [46]. Their
potential significance in predicting ARDS development
was first demonstrated by Rubin and colleagues [47] who
found that increased plasma levels of this marker exhib-
ited a high predictive value both for the development of
ARDS and for identifying patients with nonpulmonary
sepsis who were unlikely to survive. However, authors did
not use the uniform criteria for the definition of ARDS
and risk state [3], evidence that poses major limitations to
the results of the study.
Furthermore, in an aforementioned study, Kayal et al. [44]
in parallel with other findings reported a marked andRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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independent association of circulating VWF with the dis-
ease severity as assessed by other commonly applied clin-
ical variables. These findings were further supported by a
single-center study from Ware et al [48]. They conducted
the first comparative study of VWF concentrations in both
plasma and edema fluids of patients with early ALI from a
variety of causes and reported that serum VWF levels were
an independent predictor of hospital mortality and were
associated with longer duration of mechanical
ventilation. Potential criticisms of this study was the
implementation of high tidal volume ventilation that pos-
sibly increased systemic endothelial activation, the small
sample size, the lack of sequential measurement and the
fact that the studied biomarker appeared not to be
endothelial-specific since it is produced in small amounts
by platelets [36].
To streamline these observations and ameliorate potential
hardships the same group of authors {Ware et al. [49]}
carried out a multicenter study of 559 patients with ALI
and ARDS which was recently published. In accordance
with earlier studies [48], a significant correlation of ele-
vated VWF plasma levels with adverse outcomes,
including mortality, duration of unassisted ventilation
and organ failures was pointed out. Intriguingly, authors
demonstrated for the first time a negative association
between markers of endothelial activation and presence
or absence of sepsis, supporting the hypothesis that ALI
might be an independent cause of systemic endothelial
activation and injury. Finally, in the same study no mod-
ulation of plasma VWF concentrations by protective
mechanical ventilation was observed. Despite the remark-
able power of the presented findings, there are substantial
weaknesses that deserve further investigations including
the inconclusive analysis of the plasma VWF levels associ-
ated with patients' mortality, the lack of definite knowl-
edge regarding the source of VWF production, and the
mechanisms leading to increased peripheral concentra-
tions since the latter also could reflect decreased clearance
from the circulation.
Subsequent data derived from other studies [50-54] was
rather contradictive and controversial. Even though,
Moalli et al. [50] found a poor predictive value of serum
VWF levels for the development of ARDS in a group of at
risk patients, the biomarker concentrations were corre-
lated with the disease severity,. Similarly, Moss et al. [51]
plotted ROC curves and concluded that in patients at risk
for ALI/ARDS from multiple causes, serum VWF levels
failed to reliably discriminate which patients would
develop ARDS. The evidence was further validated by Sab-
harwal et al [52]. Authors conducted the first study com-
paring plasma levels between survivors and nonsurvivors
in a group of patients both at risk for and with established
ARDS and observed no significant association of VWF
blood levels with patients' mortality ;predictive value of
the marker was not reported. In agreement with the previ-
ous study, a study from the same group of scientists {Bajaj
et al. [53]} using standard criteria for the definition of
ARDS and at risk state [3] demonstrated the inability of
three endothelial-specific proteins including VWF to pre-
dict the progression of ARDS in at risk patients. Nonethe-
less, major caveats that should be addressed include the
fact that many at-risk patients had already some degree of
ALI, the lack of serial measurement that could potentially
show a trend towards prediction of ARDS development
and the causal diversity of patients examined that could
possibly affect the results of the study. The latter limita-
tion was addressed by Moss et al. [54] who established
that the degree of endothelial activation as determined by
the plasma levels of VWF (higher in subjects with sepsis
than patients with trauma) is not uniform in all patients
at risk for developing ARDS.
Accumulated evidence from the preceding studies suggest
that the etiologic diversity of patients enrolled renders
major uncertainty to the reliability of the results and high-
lights the necessity for further prospective studies using
standard criteria for the definition of ARDS and analyzing
well defined and uniform group of at risk patients in order
to produce knowledge of high scientific rigidity. Direct
comparison of the different studies is difficult and in a
way meaningless because of the use of varying definitions
for ARDS and at-risk patients as well as the inclusion of
different patient populations, in which of them some
degree of ALI was probably already present (Tables 3a and
3b).
Markers of neutrophil activation (Table 6)
Generally, it is strongly believed that ARDS arises as a
result of tissue injury secondary to sequestration of
inflammatory cells, tissue invasion, and secretion of cyto-
toxic products. Neutrophils have received much attention
as key part of this process. Although ARDS has been
described in neutropenic patients [16,55] there is
increased evidence implicating neutrophils in most cases
of ARDS. They have been reported by several studies
[56,57] to exert an important role in the early phase of ALI
characterized by architecture remodeling, surfactant and
epithelial toxicity. They use a wide array of enzymes dur-
ing the process of transmigration through biological
membranes such as alveolar-capillary barrier [58]. These
enzymes include, metalloproteinases (MMPs) such as
MMP-9 also called gelatinase B which is secreted from pre-
formed neutrophil granules in response to a variety of
stimuli including proinflammatory cytokines (IL-8,
TNFa). MMP-9 is secreted as a zymogen, and then acti-
vated by a variety of other proteases such as elastase, and
plays a crucial role in digesting basement membranes
[58,59]. Therefore, it has been speculated that metallopro-Respiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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teinases probing aspects of the inflammatory response
could be utilized as markers of neutrophil activation and
subsequently to reflect disease activity and severity, shed-
ding further light into the pathogenesis of ARDS.
Fueled by this prospect, Pugin et al. [60] compared the
concentrations of proinflammatory cytokines and colla-
genases in serum and pulmonary oedema fluids in a small
group of patients with ARDS and hydrostatic oedema
from congestive heart failure. Authors concluded that ele-
vated pulmonary oedema levels of these mediators could
differentiate between these conditions, whereas plasma
levels of proinflammatory and metalloproteinase activity
proved to be of poor discriminative value. The latter
observation mirrors the hypothesis that the inflammatory
response characterizing ARDS patients is well compart-
mentalized, with little spillover into the circulation and
that the measurement of circulating proinflammatory
cytokines without the appreciation of their inhibitors or
receptor antagonists is misleading mainly due to a possi-
ble neutralization.
To gain a more comprehensive understanding on the role
that neutrophils exhibit during the inflammatory cascade
resulting to ALI, investigators scrutinized the utility of
other chemotactic agents including leukotrienes (LTs).
LTs (B4, C4, D4, E4) exert a synergistic role with IL-8 in
the neutrophil influx and activation leading to a massive
recruitment of neutrophils and to a catastrophic
inflammatory response. Their BALF levels have been
found elevated in patients with ARDS and their involve-
ment in the alterations of microvascular permeability cor-
related with the accumulation of pulmonary oedema has
been suggested [61-63].
Moreover, Amat et al [64] utilizing ROC curve analysis
demonstrated that LTB4 plasma levels could serve as a val-
uable predictive marker of ARDS in terms of specificity
and sensitivity. In the same study, authors performed
serial measurement and reported a strong association of
both LTB4 and IL-8 peripheral concentrations with the
patients' survival. However, the small number of patients
enrolled, the lack of adjustment with the disease severity
and the inability of LTB4 plasma levels to be an independ-
ent predictive marker arise major concerns whether they
could monitor disease behaviour and predict ARDS devel-
opment in at risk patients (Table 6).
Table 6: Studies measuring markers of neutrophil activation and ferritin in patients with or at risk for ARDS
Investigator Patients 
Controls
Biomarker / Summary ROC curve analysis 
Cut-off values
Specificity – 
Sensitivity PPV – 
NPV
Limitations
Pugin et al. 60 31 at risk
23 ARDSa
IL-8, MMP-2, MMP-9
Plasma levels of inflammatory 
activity are not useful markers 
in differentiating permeability 
from hydrostatic pulmonary 
edema
No Not estimated Measurement of circulating 
proinflammatory cytokines 
without the appreciation of 
their inhibitors or receptor 
antagonists is misleading 
mainly due to a possible 
neutralization
Small number of patients
No ROC curve analysis / 
cut-off values
Amat et al. 64 21 ARDSa
14 at risk
Strong association of LTB4 and 
IL-8 serum levels with the 
patients' survival.
Yes
LTB4: 14 pmol/ml
IL-8: 150 pmol/ml
LTB4 + IL-8: 88-70-
85-75% (markers of 
mortality rate)
LTB4 : 85-72-20-98% 
(marker of ARDS 
development)
Small sample size
Lack of adjustment with 
the disease severity
Inability of LTB4 plasma 
levels to be an independent 
predictive marker
Connelly et al. 66 75 at risk
8 ARDSa
Serum ferritin is a sensitive and 
specific predictor of ARDS 
development
Yes
Ferritin (male):270 ng/ml
Ferritin (female): 680 ng/ml
71-83-86-67%
90-60-82-75%
Limited number of ARDS 
patients
Heterogeneity of studied 
population
Sharkey et al. 67 42 at risk
16 ARDSa
Correlation of ferritin plasma 
levels with the development of 
ARDS, multiple organ failure 
and severity of lung injury
Yes
Ferritin (male):270 ng/ml
Ferritin (female): 680 ng/ml
64-73-75-62%
92-60-95-75%
Inadequate sample volume
Not specific cut-off values
Elevated serum levels may 
reflect a systemic response 
to a risk factor
Abbreviations: ARDS: Acute Respiratory Distress Syndrome, IL: Interleukin, LTB4: Leukotriene B4, MMP-Metalloproteinase, NPV: Negative 
Predictive Value, PPV: Positive Predictive Value, ROC: Receiver Operating Characteristic, a: Use the American European Consensus Conference 
definitionsRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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Ferritin (Table 6)
Ferritin is a 480-kDa iron-storage protein that sequesters
iron in the ferric (Fe3+) state. It has been speculated that
ferritin may serve as a crucial antioxidant mediator
because free iron enhances the formation of highly toxic
hydroxyl radicals from superoxide anion and hydrogen
peroxide. On the other hand, oxidative stress is a
condition commonly seen in disorders at risk for ARDS
development such as sepsis. Hence, ferritin-derived iron
may aggravate oxidative damage in critically ill patients,
contributing to the pathologic abnormalities encountered
in ARDS. Furthermore, proinflammatory cytokines such
as IL-8, IL-6 and TNFa which are increased and presuma-
bly participating in the pathogenetic derangements of
ARDS have been suggested to promote ferritin synthesis
[39,65]. Thereby, it can be concluded that elevated ferritin
levels could result from oxidative stress, proinflammatory
cytokines and the degree of lung injury, all conditions
characterizing the pathogenesis of ARDS and
subsequently can be used as prognostic and monitoring
tool reflecting the likelihood of ARDS development and
the disease severity.
The first study attempted to prove such correlation was
conducted by Connelly et al [66]. They plotted ROC
curves to estimate the utility of ferritin levels as prognostic
factors and produced clinically useful cut-off points which
could predict the development of ARDS with high
sensitivity, specificity, negative and positive predictive
value, both in male and female predominantly septic sub-
jects. However, the heterogeneity of the etiologic factors
resulting to ARDS development in at risk patients renders
major uncertainty to the rigidity and reliability of the
results.
To ameliorate this hardship, the same group of authors
{Sharkey et al. [67]} generalized and extended the latter
results in a homogeneous group of at-risk patients with
multiple trauma demonstrating a strong correlation of
initial ferritin plasma levels with the development of
ARDS and multiple organ failure. In addition, an associa-
tion of serum ferritin levels with the severity of lung injury
as well as other markers of endothelial activation was also
noted supporting the premise that elevated levels could
reflect the inflammatory status encountering in ALI.
Nonetheless, authors failed to detect specific predictive
cut-off values suggesting that circulating concentrations of
this biomarker are unable to predict per se the progression
to ARDS. A possible explanation could arise from the
hypothesis that elevated levels of this marker must reflect
a systemic response to a risk factor, which may prove to
reduce its specificity (Table 6).
Lung epithelium-specific proteins (Table 7)
Beyond other important functions, the lung epithelium
produces complex secretions, including mucus blanket,
surfactant proteins, as well as several proteins important
for host defense [68].
Sampling the epithelial lining fluid by bronchoalveolar
lavage (BAL) represents the common means of studying
the proteins secreted by the lung epithelium and investi-
gating their alterations in lung disorders [69]. However,
the past fifteen years pioneering studies [70] showed the
presence of these proteins in the bloodstream as well,
even though in small amounts. Because these proteins are
mainly, if not exclusively secreted within the respiratory
tract, their occurrence in the vascular compartment can be
explained by several hypothetical mechanisms including,
leakage from the lung into the bloodstream, increased
production by the alveolar type II cells or diminished
clearance rates from the circulation [68].
Surfactant-associated Proteins
Pulmonary surfactant is a complex and highly surface
active material covering the alveolar space of the lung.
Biochemically, surfactant is a molecular mixture com-
posed mainly of structurally heterogeneous phospholip-
ids. A major function of pulmonary surfactant is to reduce
the surface tension at the air-liquid interface of the alveo-
lus, thereby preventing alveolar collapse on expiration. It
has also been demonstrated that the surfactant contains
specific proteins [71]. Four surfactant-specific proteins
with different structural and functional properties have so
far been identified. They were named surfactant protein-
(SP)-A, SP-B, SP-C and SP-D according to the chronologic
order of their discovery [72] and have been divided in two
distinctive groups, the low-molecular-weight hydropho-
bic SP-B and SP-C and the high-molecular-weight-
hydrophilic SP-A and SP-D. The latter belong to the
collectin subgroup of the C-type lectin superfamily and
are produced by two types of non-ciliated epithelial cells
in the peripheral airway, Clara cells and alveolar type II
cells. Studies have demonstrated that SP-B and SP-C seem
to play an essential role for the adsorption of phospholi-
pids to the air-water interface resulting to a stable phos-
pholipids film and for the dynamic surface-tension-
lowering properties [73]. Additional functions of the alve-
olar surfactant system include prevention of alveolar
edema [74] and a pronounced influence, especially of the
collectins SP-A and SP-D in the innate immune system of
the lung [75,76] and have been used as useful markers for
confirming the diagnosis and evaluation of disease activ-
ity of various ILDs since they reflect the epithelial damage
and turnover [77]. Thus, it has been speculated that alter-
ations of SPs in biological fluids could serve as valuable
markers of the severity of the lung injury or clinical out-
come in ARDS patients.Respiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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Most of our knowledge regarding changes in SP concen-
trations that occur in patients with or at risk for ARDS and
their value in reflecting the disease severity or the likeli-
hood of ARDS development comes from BAL studies. Sev-
eral reports in the literature have demonstrated the
occurrence of low SP-A levels in BALF of patients with
ARDS following trauma [78,79] coupled with a strong
relation of this biological marker to the severity of
endothelial damage [80]. Moreover, a potential value of
SP-A plasma levels in discriminating patients with ALI of
various etiologic factors has also been shown [79]. On the
other hand, little is known about changes in peripheral
concentrations of surfactant-associated proteins in
patients with ALI and whether these alterations can serve
Table 7: Studies measuring lung-specific proteins in patients with or at risk for ARDS
Investigator Patients 
Controls
Biomarker / Summary ROC curve 
analysis Cut-off 
values
Specificity – 
Sensitivity 
Diagnostic 
accuracy
Limitations
Doyle et al. 81 15 ARDSa
10 at risk
10 controls
SP-A is an acute indicator of 
lung function and 
alveolocapillary membrane 
injury
No Not estimated Small number of patients
No ROC curve analysis / cut-off 
values
No definitive relation with disease 
severity
Doyle et al. 82 22 ARDSa
10 at risk
33 controls
Superiority of SP-B compared to 
SP-A plasma levels as a marker 
of lung function and 
alveolocapillary membrane 
injury
No Not estimated Only 3 case-control studies
Inadequate sample size
Lack of adjustment with disease 
behaviour
No ROC curve analysis / cut-off 
values
Greene et al. 83 41 ARDSa
22 at risk
35 controls
SP-A, SP-B, SP-D
Serum changes found to be 
neither sensitive nor specific in 
predicting the onset of ARDS 
and discriminating survivors 
from non-survivors.
Yes
Not reported
Poor predictive 
value
Low specificity/
sensitivity
Limited number of patients
Serial measurements for a short 
period of time/ Lack of serial 
measurement for the most severe 
forms
Heterogeneity of studied population
Poor predictive value for serum 
levels
Cheng et al. 84 36 ARDSa
2 ALI
SP-A levels were associated 
with severity of clinical lung 
injury and with disease outcome
No Not estimated Small sample size
Causal diversity of studied 
population
No serial measurement
Greene et al. 85 51 at risk
26 ARDSa
16 controls
SP-A levels are predictive for at 
risk patients who developed 
ARDS from sepsis and 
aspiration but not trauma
No Not estimated Small sample size
No ROC curve analysis / cut-off 
levels
Bersten et al. 86 54 at risk
9 controls
SP-B but not SP-A cut-off 
plasma levels predict ARDS 
development, particularly in at-
risk patients suffering a direct 
lung injury
Yes
SP-B: 4.994 ng/ml
78-85-85-78% Small number of patients
Limited follow-up serum data
Most of patients had already lung 
injury
Exclusion of milder at risk patients
Eisner et al. 87 565
ALI/ ARDSa
SP-A, SP-D
Attenuation of SP-D plasma 
levels by lower volume 
ventilation strategies
No Not estimated Only 2 serial measurements
Heterogeneity of studied population 
Potential selection bias
No ROC curve analysis / cut-off 
levels
Ishizaka et al. 95 35 at risk
27 ARDSa
21 controls
Association of optimal cut-off 
values of KL-6 serum levels with 
patients' mortality
Yes
KL-6: 253 U/ml
100-87% Inadequate sample volume
Heterogeneity of studied population
Sato et al. 96 28 ARDSa
10 controls
Association of KL-6 serum 
levels with variables of lung 
injury severity and with 
mortality rates
No correlation with ventilation 
strategies
No Not estimated Small sample size
Heterogeneity of studied group
No serial measurement
No ROC curve analysis / cut-off 
levels
Diversity of ventilatory treatment
Abbreviations: ALI: Acute Lung Injury, ARDS: Acute Respiratory Distress Syndrome, BAL: Bronchoalveolar Lavage, KL-6: Krebs von den Lungen-6, 
ROC: Receiver Operating Characteristic, SP: Surfactant Protein, a: Use the American European Consensus Conference definitionsRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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as markers of injury to the epithelial and endothelial bar-
riers in the lungs.
Doyle et al. [81] documented elevated circulating concen-
trations of SP-A in patients with ARDS and in those with
acute cardiogenic pulmonary edema possibly resulting
from increased alveolocapillary permeability due to exces-
sively high pulmonary capillary pressures. In the same
study, blood SP-A levels were inversely associated with
blood oxygenation and static respiratory system compli-
ance. These results were fully confirmed by the same
group of authors {Doyle et al. [82]} who also illustrated
a clear superiority of SP-B compared to SP-A plasma levels
as a marker of lung function and alveolocapillary mem-
brane injury.
Another study by Greene et al. [83], evaluated the differ-
ences that occur in SPs in BALF and serum of a relatively
small cohort of patients at risk for ARDS and during the
course of the syndrome. Authors demonstrated that only
SP-A and SP-D BALF levels were strongly related to out-
come and likelihood of disease progression whereas
serum changes found to be neither sensitive nor specific
in predicting the onset of ARDS and discriminating survi-
vors from non-survivors.
These data were further confirmed by a small cohort
observational study by Cheng et al [84]. Even though
authors reported an association of elevated SP-A plasma
levels with a high degree of lung injury, they failed to
extend this correlation with the disease mortality. Moreo-
ver, serum SP-D levels exhibited weak relation to the dis-
ease severity. It should also be noted that the
aforementioned results present low statistical power due
to the limited number of patients, the causal heterogene-
ity of the studied group and the absence of serial
measurement and therefore no meaningful outcome can
be excluded.
In harmony with the latter results, Greene et al. [85] found
that plasma SP-A was weakly predictive for ARDS develop-
ment in septic patients and were unable to detect at risk
trauma patients that developed the syndrome. Addition-
ally, authors raised the crucial issue whether circulating
SPs can reflect pathophysiologic differences between
direct and indirect causes of ARDS and subsequently
detect biologic changes early after an insult. From a prag-
matic clinical perspective the most important question to
be answered is which ICU patients requiring ventilatory
assistance will develop ARDS.
To do so Bersten et al. [86] generated ROC curve analysis
and identified practical thresholds for SP-B plasma levels
that could be clinically useful in predicting ARDS devel-
opment, particularly in at-risk patients suffering a direct
lung injury. In consistency with earlier studies [83-85] SP-
A blood levels added no significant information on the
disease prognosis. Further, an increase of circulating SP-B
concentrations was documented on study entry, before
changes in commonly applied clinical variables for the
assessment of lung injury become apparent. These find-
ings emphasize the usefulness of surfactant-associated
proteins for the early detection of ARDS pathophysiologic
alterations preceding changes in clinical parameters such
as respiratory dysfunction. Arguments that can be made
include the small sample size, the limited sequential
measurements and the exclusion from the study recruit-
ment of at risk patients with milder pulmonary dysfunc-
tion. These caveats coupled with the evidence that a
considerable number of patients studied had already lung
injury, pose major limitations to the predictive capacity of
SP-B plasma levels and raise the necessity for larger pro-
spective studies.
The only so far large multicenter randomized controlled
trial was performed by Eisner et al. [87] who estimated the
prognostic value of SP-A and SP-D levels in an overall of
565 patients with early ALI/ARDS. Authors conducted the
first study with adequate statistical power to examine the
impact of SPs on mortality and other clinical variables
and clearly demonstrated a strong linkage of elevated SP-
D levels with worse clinical outcomes such as greater risk
of death, fewer ventilator- free and organ failure-free days.
One of the most remarkable ascertainments of this study
was the attenuation of SP-D plasma levels by the lower
volume ventilation strategies which reduces patients'
mortality postulating for the first time a significant associ-
ation of biological parameters with therapeutic
approaches and subsequently emphasizing the role of this
mediator as a marker of the disease severity and progno-
sis. However, this study exhibited substantial weaknesses
including the lack of sufficient serial measurements, a
potential selection bias of patients recruited and the diver-
sity of predisposing factors for ARDS development. These
observations are not to diminish their value as prognostic
and monitoring tools but to highlight the need for further
confirmation studies using independent and well-defined
populations of ALI/ARDS patients.
Mucin-associated Antigens
Mucins are major components of the mucus layer cover-
ing the airway epithelium. They consist of high-molecu-
lar-weight glycoproteins belonging to a broad family of
mucin peptides [68]. Mucins are either associated with
membranes or secreted at the surface of the respiratory
tract [68]. Krebs von den Lungen-(KL)-6 is mainly associ-
ated with cellular membranes. It was initially described by
Kohno et al. [70] as a high-molecular-weight glycoprotein
and was classified as human MUC1 mucin. Immunohis-
tochemistry has mainly detected KL-6 in alveolar type IIRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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and epithelial cells of the respiratory bronchioles. KL-6 is
predominantly expressed by airway cells; however, is not
entirely lung specific, since it is also present on other
somatic cells, such as pancreatic cells, eosophageal cells
and fundic cells of the stomach [88]. Additionally, KL-6 is
a sensitive indicator of damage to alveolar type II cells,
which strongly express this mucin at their surface [70].
Type II pneumonocytes are regenerated over the alveolar
basement membrane after the death of type I pneumono-
cytes over the first stage of lung injury. Therefore, its raise
would theoretically represent the destruction of the nor-
mal lung parenchyma and architecture, the increased per-
meability of the air-blood barrier as long as the
regenerating process as expressed by type II pneumono-
cytes' activity.
Towards this direction, the presence of KL-6 has been
extensively used with great promises to monitor the sever-
ity of disease in idiopathic pulmonary fibrosis [89-91]
and other interstitial lung diseases [92-94]. Since damage
to, and disruption of, the alveolar epithelial lining cou-
pled with loss of integrity of the air-blood barrier repre-
sent key features in the pathophysiology of ARDS, KL-6
serum levels could potentially serve as valuable indicators
of the disease severity directly assessing the degree of epi-
thelial damage and predicting the progression to ARDS.
Nevertheless, only few studies so far, have evaluated their
monitoring and prognostic efficacy in patients with or at
risk for ARDS development.
One of the first studies to do so was recently carried out by
Ishizaka and co-workers [95]. Authors generated ROC
curve analysis and documented a highly sensitive and spe-
cific association of optimal cut-off values of KL-6 serum
levels with patients' mortality. The latter, further supports
the premise that disruption of the alveolar barrier
represents a major determinant of prognosis of ALI and
that serial measurements of KL-6 plasma levels might be
helpful markers of the disease progression. Limitations
that should be addressed include the limited number of
patients, the retrospective analysis of the results and the
diversity of the etiologic factors of ALI generate major con-
cerns about the reproducibility and the reliability of the
data.
Recently, Sato et al. [96] sought to determine potential
correlations of KL-6 circulating concentrations with dis-
ease severity, patients' survival and different predisposing
factors of ARDS. The most remarkable ascertainments of
this study include strong associations of KL-6 peripheral
levels with variables of lung injury severity and with the
rates of mortality indicating possible relationship
between the degree of epithelial damage and poor out-
come in ARDS. Even though, authors attempted to show
a modulation of KL-6 serum levels by ventilatory strate-
gies, this relationship failed to reach a statistical signifi-
cance. Despite substantial weaknesses exhibited such as
the lack of serial measurement, the small sample size and
the diversity of the applied treatment data derived from
this study is highly informative and provides important
knowledge regarding the biological impact of mechanical
support strategies in this syndrome indicating the moni-
toring value of the epithelial damage markers. Further and
sizeable prospective studies are required to validate the
aforementioned hypothesis (Table 7).
Future challenges and limitations
The ARDS represents an overwhelming inflammatory
reaction to numerous insults within the pulmonary
parenchyma resulting in life-threatening derangements in
pulmonary vasomotion, alveolar ventilation and gas
exchange. ARDS is a frequent disease with a devastating
incidence between 13.5 and 75 per 100,000, thus affect-
ing about 16–18% of all patients ventilated in the ICU
[76,97]. Hence, ALI/ARDS is a major public health prob-
lem encountered frequently by all physicians who care for
critically ill patients. Despite the fact that research efforts
over the past several years have provided a more
comprehensive knowledge of the potential mechanisms
comprising the immunopathogenesis of ALI/ARDS and
led to the development of innumerable causative or
symptomatic treatment approaches, the mortality rate of
these patients remains unacceptably high at 30–40% [97].
Currently, the only therapy that has been proven to be
effective at reducing mortality is a protective ventilatory
strategy [98]. However, new therapies are still needed.
One of the most fruitful applications is monitoring the
disease activity and consequently the early identification
of at risk patients with increased likelihood of non-
response to treatment and progression to ARDS. Never-
theless, there are problems with the sensitivity, effort-
dependability and ease of repetition of the current modal-
ities being used for this purpose, including radiological
and BAL techniques as well as clinical and physiological
indices of pulmonary injury (Murray score), systemic ill-
ness (Acute Physiology and Chronic Health Evaluation-
APACHE-II score and Simplified Acute Physiological
Score -SAPS), ARDS severity (respiratory system compli-
ance and PaO2/FiO2 ratio) and multiorgan system failure
(Multi-Organ Dysfunction Score-MODS). Most of these
clinical parameters have failed to be independent predic-
tors of mortality in studies of adults with ALI/ARDS
[99,100]. Development of a prognostic index that
combines clinical and biological determinants may be
useful to ameliorate these hardships.
On the basis of this conception, a large body of serum
markers either cytokines and lung-specific proteins or
markers of endothelium and neutrophil activation as well
as other serological parameters probing different facets ofRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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the immunopathogenesis of ALI/ARDS has been deline-
ated. The applications of these markers in the clinical set-
ting created major expectations in terms of defining
categories of patients for different therapies or prognosis
for the purpose of counseling families and patients and/or
possibly identifying novel therapeutic targets. The deter-
mination of a reliable serologic marker reflecting the dis-
ease behaviour and adding independent information
regarding the development of the syndrome before it
becomes obvious in clinical level, easily reproducible and
feasible to be measured serially represents a major chal-
lenge. The early serial measurement of this biomarker
may serve as an independent non-invasive prognosticator
of the disease outcome even at the onset of the syndrome
and therefore lead to an early detection of at risk patients
with increased likelihood of progression to ARDS. The lat-
ter, if sufficiently accurate, could prove extremely useful in
identifying and counseling families of patients at low or
high risk for adverse outcomes and further, will allow ven-
tilatory or other types of treatment to be evaluated or
eventually modulated before they have failed in the high
risk group. The presented data give credence to the view
that multiple biomarkers can be used to measure the lung
and systemic response to a protective ventilatory strategy
and potentially to discriminate patients who are ineffec-
tively treated and might be candidates for rescue therapies
[49,87].
More importantly, use of one or more of these biologic
markers to select a group of patients at higher risk of
adverse clinical outcome could be used to restrict or strat-
ify enrollment in future clinical trials applying novel ven-
tilator treatments such as high-frequency oscillatory
ventilation leading to a better patient care. Thereby, a
combination of clinical factors and biologic marker meas-
urements could be crucial for the selection of more
homogeneous groups of patients with ALI/ARDS for fur-
ther studies producing evidence of high scientific rigidity
[101]. Finally, understanding the relative roles of markers
of systemic and pulmonary endothelial injury and other
inflammatory mediators to the pathogenetic process of
the syndrome is likely to lead to valuable insights into the
final pathway resulting in diffuse alveolar damage and sig-
nificant lung dysfunction, highlighting therapeutic targets
for novel interventions. The aforementioned components
can potentially compile a clinician's "wish list".
However, the feeling of excitement arising from the
expected clinical utility comes in contrast with important
deficiencies exhibited by the new methodologies includ-
ing non-standardization techniques, lack of knowledge of
reproducibility and link to disease behaviour. Further-
more, most of the studies enrolled a limited number of
patients, insufficient to extract any meaningful or statisti-
cally significant outcome. In addition, the heterogeneity
of the studied population resulting from the causal diver-
sity of the syndrome and the use of non-uniform criteria
for the definitions of ARDS and at-risk patients (Tables 2,
3, 4, 5) render major uncertainty to the reproducibility
and the scientific rigidity of these findings and may
explain potential discrepancies between various studies
investigating different groups of at risk patients.
Moreover, many of the caveats arising from this data are
generated by the origin disadvantages of the investigated
serological parameters to serve as specific markers of the
disease activity and severity. In particular, it is well known
that assays of circulating cytokine concentration may be
misleading, because they do not detect receptor or cellular
bound cytokines, or they may fail to detect cytokines
when inhibitors or receptor antagonists are present. Thus,
measured cytokine concentrations may not reflect the dis-
ease activity or the state of inflammation but the increased
production or decreased clearance from the circulation. In
consistency with these limitations, it should be under-
lined that cytokines are part of an inflammatory cascade
and biological effects are difficult even impossible to
interpret without the appreciation of the entire network of
the inflammatory response. Hence, data in most of the
studies was inconclusive and incomplete since none of
them analyzed serum alterations of a considerable
number of inflammatory components.
Additionally, it is of high importance to note that unfor-
tunately only few studied molecules (VWF, IL-1β , IL-6,
ICAM-1, VCAM-1) exhibited independent discriminatory
power [18,44,48,49] and associated with the mortality of
patients with high sensitivity and specificity [45]. Finally,
only the minority of the studies [18,19,25-
27,43,45,47,51,53,64,66,67,83,86,95] clarified the effec-
tiveness and the diagnostic accuracy of the biomarkers by
applying ROC curve analysis which is essential to estimate
the sensitivity and specificity of a marker and to introduce
clinically practical cut-off levels for the prediction of
ARDS development in at risk individuals.
Collectively, these findings highlight the necessity for fur-
ther investigations in the context of large prospective stud-
ies analyzing homogeneous and well defined group of
ARDS or at risk patients and the assessment of novel mol-
ecules to serve as diagnostic and prognostic tools, as well
as markers of the disease activity and severity.
Conclusion
Currently, the application status in routine clinical prac-
tice for most of these biologic markers is still in its infancy
and remains exploratory. Unfortunately, they do not yield
independent indications for therapy or mark the end of
the inflammatory process and their prognostic value still
needs to be established. Although the majority of themRespiratory Research 2005, 6:62 http://respiratory-research.com/content/6/1/62
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have not yet lived up to the "great hype" that was gener-
ated, markers of endothelium activation and mostly VWF
and adhesion molecules (ICAM-1, VCAM-1, E-selectin)
show the greatest promise in ARDS and ALI. On the con-
trary the majority of serum cytokines and ferritin appear
to be not ready for routine monitoring since they may
reflect an inflammatory response to a risk factor rather
than lung injury and disease severity. Additionally, lung
specific proteins have proven to be neither specific nor
sensitive for the prediction of ARDS development and the
disease outcome and moreover they have failed to associ-
ate with alterations in the ventilatory strategies in large
clinical trials. Further prospective investigations, technical
improvements and introduction of novel markers are war-
ranted in order to elevate the association of serum
biomarkers with the pathogenesis of ARDS in the same
status as for tumour markers with lung cancer. Neverthe-
less, crossing the boundary from research to clinical appli-
cation requires validation in multiple settings,
experimental evidence supporting a pathophysiologic
role, and ideally intervention trials showing that modifi-
cation improves the outcome. The emergence of pioneer-
ing technologies including DNA microarrays which have
already been applied with great success in the respiratory
research field [102] can help scientists to circumvent this
problem and bridge this boundary. In the interim, these
markers can be quite useful to supplement the clinical,
radiological and physiological monitoring of the disease
and identify high-risk patients who would benefit from
aggressive management of established risk factors.
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